CPHI Milan 2026 Fiera Exhibition Centre

9 Oct 2026

Kangrong’s Executive Team at CPHI Milan

The executive team of Kangrong Pharmaceuticals attended the CPHI 2026 in Milan earlier this month from 6th October to 8th October. CPHI is the largest pharmaceutical ingredients and technology exhibition held in the world, with 2,400+ exhibiting companies from 160+ countries at this year’s event. Attending exhibitors include experts from areas including API, generic finished product, CMO/CDMO, logistics, and innovative solutions. Whilst in attendance, Kangrong Pharmaceutical’s executive team conversed with numerous industry experts with knowledge in import/export, CMO, API manufacturing, and more. The main goal of the visit is to expand Kangrong’s reach, as well as understand current trends and challenges in the broader community. In the coming years, we are excited to explore opportunities that would allow us to introduce Kangrong’s portfolio to key players around the world.

Read more
Team Photo

5 Aug 2026

Strengthening Industry-Academia Collaboration: Tour with Students from Bozhou University School of Pharmacy

To further strengthen university–industry collaboration, promote the integration of education and industry, support the development of pharmaceutical professionals, and provide a platform connecting academic learning with industry practice, approximately 160 faculty members and students from the Pharmacy Program of Bozhou University visited our company in two groups on May 28 and June 23, 2026. To ensure that the visits were conducted safely, efficiently, and in an orderly manner, our Human Resources & Administration Department, Production Department, Quality Department, and other relevant teams worked closely together to make comprehensive preparations in advance. These included safety inspections of the facility, planning of visitor routes, coordination of guides, and access control for clean production areas. During the visits, department representatives provided detailed introductions to our production safety management systems, modern pharmaceutical manufacturing processes, and Quality Control (QC) procedures. Faculty members and students toured key areas of the company, including the clean production workshops and quality control laboratories, gaining first-hand insight into the standardized, regulated, and highly refined operations of a modern pharmaceutical company. Through this on-site learning experience, the visiting faculty and students gained a more comprehensive understanding of the entire pharmaceutical manufacturing process and the stringent quality and safety requirements of the pharmaceutical industry. The visit also helped reinforce their theoretical knowledge while providing a closer look at our rigorous quality management system and standardized corporate operations. At the same time, this university–industry exchange provided an opportunity to showcase our professional corporate culture, well-managed production environment, and established talent development system. It further strengthened the foundation for cooperation between the university and our company while enhancing our corporate presence and industry engagement. Going forward, Kangrong Pharmaceutical will continue to deepen university–industry collaboration in talent development and regularly carry out cooperative programs such as student visits, industry orientation programs, internships, and employment-related practical training. We remain committed to fulfilling our corporate social responsibility and contributing to the development of highly skilled professionals for the pharmaceutical industry. First published: 5 August, 2026

Read more
Tigecycline for Injection Approved by the NMPA

2 Jul 2026

Tigecycline for Injection Approved by the NMPA

Beijing Rongying Pharmaceutical Technology Co., Ltd. has received the Drug Registration Certificate for Tigecycline for Injection issued by the National Medical Products Administration (NMPA), with the drug approval number NMPA Approval No. H20265029 . Rongying Pharmaceutical is the R&D centre of Kangrong Pharmaceutical. Tigecycline for Injection , available in a 50 mg strength, is indicated for the treatment of patients aged 18 years and older with complicated intra-abdominal infections caused by susceptible bacteria, including Citrobacter freundii , Escherichia coli , and Bacteroides fragilis ; complicated skin and soft tissue infections, including those caused by methicillin-resistant Staphylococcus aureus (MRSA); and community-acquired bacterial pneumonia. This is Kangrong Pharmaceuticals’ second injection product approved by the NMPA; the first injection product, Moxifloxacin Hydrochloride and Sodium Chloride injection, was approved in 2024. First published: 2 July, 2026

Read more
Levofloxacin Eye Drops Approved by the NMPA

15 Jun 2026

Levofloxacin Eye Drops Approved by the NMPA

Kangrong Pharmaceutical has received the Drug Registration Certificate for Levofloxacin Eye Drops issued by the National Medical Products Administration (NMPA), with the drug approval number NMPA Approval No. H20264702 . Levofloxacin Eye Drops , strength: 0.488% (5 mL: 24.4 mg) (calculated as C₁₈H₂₀FN₃O₄), are primarily indicated for the treatment of blepharitis, hordeolum, dacryocystitis, conjunctivitis, meibomianitis, and keratitis, as well as for antimicrobial prophylaxis during the perioperative period in ophthalmic surgery. First published: 15 June, 2026

Read more
Inspection and Research Tour by Officials from the Anhui Provincial Medical Products Administration to Our Company

8 May 2026

Inspection and Research Tour by Officials from the Anhui Provincial Medical Products Administration to Our Company

On April 22, 2026, Zhang Lei, Member of the Party Leadership Group and Deputy Director of the Anhui Provincial Medical Products Administration, together with Wang Changxiang, Director of the Drug Manufacturing Supervision Division, and other officials, visited Kangrong Pharmaceutical to learn about the company’s development and quality management practices. During the visit, the delegation held an in-depth discussion with company representatives regarding business operations and the company’s practical needs. At the meeting, General Manager Yang Chunjie provided the delegation with a detailed overview of the company’s current development and future plans, production arrangements for existing products, and registration applications for products under development. Particular emphasis was placed on the contract manufacturing and quality assurance of Moxifloxacin Hydrochloride and Sodium Chloride Injection, a product included in China’s centralized procurement program. Deputy Director Zhang recognized the company’s positive development momentum and strong commitment to quality management, encouraging Kangrong Pharmaceutical to continue expanding and strengthening its business. He also provided comprehensive responses to the practical challenges raised by the company and expressed close attention to its development needs. Deputy Director Zhang further emphasized that pharmaceutical safety is directly related to public health and well-being. He urged the company to maintain its current positive momentum, strictly comply with the requirements and guidelines issued by the National Medical Products Administration (NMPA) and the Anhui Provincial Medical Products Administration, and place particular emphasis on post-marketing risk management to ensure the safety and health of patients. On behalf of the company, General Manager Yang Chunjie expressed his appreciation to the Anhui Provincial Medical Products Administration for fostering a supportive business environment and establishing effective communication and service mechanisms. He reaffirmed Kangrong Pharmaceutical’s commitment to continuously strengthening its core competitiveness and contributing to the sustainable development and advancement of the pharmaceutical industry. First published: 8 May, 2026

Read more
Kangrong employees join in for a spring day team building trip.

30 Apr 2026

Spring Team Building Day Trip

On April 17, over forty employees of Kangrong Pharmaceuticals gathered at the Bai Cao Garden in Qiaocheng District, Bozhou, for a spring day trip with the theme “Embracing Spring”. This was an event organised by Kangrong Pharmaceuticals, such that members of Kangrong had a chance to enjoy nature and unwind outside of their professional responsibilities. It also aimed to provide an informal environment for fostering better communication between colleagues, thereby bringing the team together and further strengthening the cooperative atmosphere at the company. On the day, the company provided a wide selection of food and drinks for the participants. The team enjoyed cookery events such as on-site BBQ and picnic. Audio equipment and karaoke machines were also available for a fun and memorable day. Overall, members of the Kangrong family showed great enthusiasm during their participation at the event, and reflected positively when later surveyed.

Read more
Lacosamide Oral Solution Approved by the NMPA

6 Jan 2026

Lacosamide Oral Solution Approved by the NMPA

Kangrong Pharmaceutical’s Lacosamide Oral Solution has recently received regulatory approval from the National Medical Products Administration (NMPA), with the drug approval number NMPA Approval No. H20256504 . The product is available in a strength of 200 mL: 2g . Lacosamide is an analogue of D-serine, an endogenous amino acid that acts as a modulator of NMDA receptors. In vitro electrophysiological studies have shown that lacosamide selectively enhances the slow inactivation of voltage-gated sodium channels (VGSCs), thereby stabilising hyperexcitable neuronal membranes. Lacosamide Oral Solution is primarily indicated as adjunctive therapy for the treatment of partial-onset seizures in patients with epilepsy aged 4 years and older. First published: 6 January, 2026

Read more
Memantine Hydrochloride Oral Solution Approved by the NMPA

23 Dec 2025

Memantine Hydrochloride Oral Solution Approved by the NMPA

Anhui Kangrong Pharmaceutical Co., Ltd.’s Memantine Hydrochloride Oral Solution has recently received regulatory approval from the National Medical Products Administration (NMPA), with the drug approval number NMPA Approval No. H20256289 . The product is available in a strength of 120 mL: 0.24 g . Memantine Hydrochloride Oral Solution is clinically indicated for the treatment of moderate to severe Alzheimer’s dementia. Its mechanism of action primarily involves antagonism of NMDA receptors, helping to reduce neuronal damage and improve cognitive function. First published: 23 December, 2025

Read more